Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Reader Response: Guillain-Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial
Neurology  (IF9.91),  Pub Date : 2021-10-26, DOI: 10.1212/wnl.0000000000012732
Justin Willer

Caution is necessary because vaccines may not have just one effect on the risk of Guillain-Barré syndrome (GBS) but a dual effect. Vaccination reduces the risk of GBS by decreasing the risk of infection. On the other hand, vaccines also have a direct effect that increases the risk of GBS by producing antibodies that cross-react with antigens of the peripheral nerves.